Abstract
Background: Humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurs within the first weeks after coronavirus disease 2019 (COVID-19). Those antibodies exert a neutralizing activity against SARS-CoV-2, whose evolution over time after COVID-19 as well as efficiency against novel variants are poorly characterized.
Methods: In this prospective study, sera of 107 patients hospitalized with COVID-19 were collected at 3 and 6 months postinfection. We performed quantitative neutralization experiments on top of high-throughput serological assays evaluating anti-spike (S) and anti-nucleocapsid (NP) immunoglobulin G (IgG).
Results: Levels of seroneutralization and IgG rates against the ancestral strain decreased significantly over time. After 6 months, 2.8% of the patients had a negative serological status for both anti-S and anti-NP IgG. However, all sera had a persistent and effective neutralizing effect against SARS-CoV-2. IgG levels correlated with seroneutralization, and this correlation was stronger for anti-S than for anti-NP antibodies. The level of seroneutralization quantified at 6 months correlated with markers of initial severity, notably admission to intensive care units and the need for mechanical invasive ventilation. In addition, sera collected at 6 months were tested against multiple SARS-CoV-2 variants and showed efficient neutralizing effects against the D614G, B.1.1.7, and P.1 variants but significantly weaker activity against the B.1.351 variant.
Conclusions: Decrease in IgG rates and serological assays becoming negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the ancestral strain and the D614G, B.1.1.7, and P.1 variants for at least 6 months in patients previously hospitalized for COVID-19. A weaker protection was, however, observed for the B.1.351 variant.
【초록키워드】 COVID-19, coronavirus disease, Evolution, antibodies, SARS-CoV-2, IgG, Coronavirus disease 2019, coronavirus, Hospitalized, antibody, B.1.351, neutralization, severity, Prospective Study, variant, SARS-CoV-2 variant, intensive care unit, severe acute respiratory syndrome Coronavirus, invasive ventilation, Neutralizing activity, Immunoglobulin G, intensive care units, Serological assay, Humoral response, Immunoglobulin, SARS-CoV-2 variants, B.1.1.7, serological assays, sera, Patient, D614G, P.1 variant, neutralizing capacity, experiment, respiratory, correlation, serological, Quantitative, Admission, Anti-spike, marker, Efficiency, humoral, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, B.1.351 variant, IgG levels, anti-S, P.1 variants, neutralizing effect, effective, Postinfection, initial, tested, performed, collected, significantly, the patient, addition, characterized, occur, correlated, Level, sustained, quantified, IgG level, patients hospitalized, with COVID-19, 【제목키워드】 coronavirus 2, activity, Multiple, Against, Month,